GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of ...

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...